The Mass Spectrometry (MS) Shared Resource offers a wide range of analytical capabilities to support the needs of UTHSCSA investigators and others in the nearby research community. The core facility is directed by Susan T. Weintraub, Ph.D., and is located on the main UTHSCSA campus. The facility includes the following instrumentation: 1) Finnigan LCQ ion trap mass spectrometer capable of nanospray and micro-HPLC-ESI/MSn measurements, used in conjunction with a Michrom BioResources MAGIC 2002 micro-HPLC; 2) Applied Biosystems Voyager DE-STR MALDI-TOF/MS; 3) Applied Biosystems Voyager Elite MALDI-TOF/MS; and 4) Finnigan SSQ700 quadrupole mass spectrometer which is able to perform GC/MS and direct probe analyses using electron impact and chemical ionization with positive and negative ion detection. A satellite facility of the MS Core has been established at the Institute of Biotechnology within the Texas Research Park, which is located 20 miles from the UTHSCSA main campus. The satellite unit encompasses a 200 sq. ft. laboratory and includes the following instrumentation: 1) an Applied Biosystems Voyager DE-PRO Biospectrometry workstation, consisting of a high performance integrated MALDI-TOF mass spectrometer, a SymBiot I Sample Workstation, and a PS-1 sample handling and data analysis system; and 2) a Thermo Finnigan integrated LC/MS system consisting of a Surveyor HPLC coupled in-line with a Finnigan LCQ DUO ion trap mass spectrometer with MS/MS capability. Major services provided to SACI investigators by the MS Shared Resource include: molecular mass determination; protein identification from solution or polyacrylamide gel; sequence analysis; elucidation of sites of post-translational modification, focusing on phosphorylation. Detection limits in the sub-picomole range are routinely obtained, making it possible to realistically characterize proteins and peptides isolated from biological samples.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-12
Application #
6689703
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-08-26
Project End
2006-07-31
Budget Start
Budget End
Support Year
12
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Ctrc Research Foundation
Department
Type
DUNS #
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Yu, Xiaojie; Zhang, Yiqiang; Cavazos, David et al. (2018) miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis 9:193
Chen, Chen; Zhao, Shujie; Karnad, Anand et al. (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :

Showing the most recent 10 out of 989 publications